FLUPHENAZINE DECANOATE vs placebo: Leaving the study early
- Population
- patients with schizophrenia
- Intervention
- FLUPHENAZINE DECANOATE
- Comparison
- placebo
- Outcome
- Leaving the study early
It is very uncertain whether FLUPHENAZINE DECANOATE changes leaving the study early compared with PLACEBO (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
FLUPHENAZINE DECANOATE vs PLACEBO Leaving the study early · patients with schizophrenia It is very uncertain whether FLUPHENAZINE DECANOATE changes leaving the study early compared with PLACEBO (very low certainty). Fluphenazine decanoate (depot) and enanthate for schizophrenia (2015) · Cochrane Headline outcomes only | RR 1.3 [0.77, 2.19] | 4 studies · 216 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS · patients with schizophrenia · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.